

SIERRA LEONE
Support for Human Papillomavirus Vaccine (HPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Sierra Leone				
2. Grant numbers: 1921-SLE-19b-X; 19-SLE-08f-Y				
3. Date of Decision Letter: 9 October 2018				
4. Date of the Partnership Framework Agreement: 10 March 2013				
5. Programme title: New Vaccine Support (NVS), HPV Routine				
6. Vaccine type: Human Papillomavirus				
7. Requested product presentation and formulation of vaccine: HPV Quadrivalent, 1 dose per vial, LIQUID				
8. Programme duration¹: 2019-2021				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)				
	2019	2020	2021	Total²
Programme Budget (Routine) (US\$)	1,155,000	951,500	852,000	2,958,500
10. Vaccine introduction grant (in US\$):				
A VIG of US\$ 255,321.60 for the introduction is payable before vaccine introduction.				
VIG Funds to be channelled through UNICEF in line with Interim arrangements (as of 1 October 2018)				

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

11. Gavi Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)³

Type of supplies to be purchased with Gavi funds in each year (Routine)	2019
Number of HPV vaccines doses	253,700
Annual Amounts (US\$)	1,155,000

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. Self-procurement: Not applicable

14. Co-financing obligations: Reference code: 1921-SLE-19b-X-C
According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds each year	2019	2020	2021
Number of vaccine doses	11,700	9,600	8,600
Number of AD syringes			
Number of safety boxes			
Value of vaccine doses (US\$)	US\$52,449	US\$43,200	US\$38,682
Total co-financing payments (US\$) (including freight)	US\$53,500	US\$44,000	US\$39,500

15. Additional reporting requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May of each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

16. Financial clarifications: VIG Funds to be channelled through UNICEF in line with Interim arrangements (as of 1 October 2018)

³ This is the amount that Gavi has approved.

17. **Other conditions:** Not applicable

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

9 October 2018